Amino acid substitutions in the cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents.

Antimicrobial Agents and Chemotherapy
D SanglardJ Bille

Abstract

The cytochrome P-450 lanosterol 14alpha-demethylase (CYP51A1) of yeasts is involved in an important step in the biosynthesis of ergosterol. Since CYP51A1 is the target of azole antifungal agents, this enzyme is potentially prone to alterations leading to resistance to these agents. Among them, a decrease in the affinity of CYP51A1 for these agents is possible. We showed in a group of Candida albicans isolates from AIDS patients that multidrug efflux transporters were playing an important role in the resistance of C. albicans to azole antifungal agents, but without excluding the involvement of other factors (D. Sanglard, K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother. 39:2378-2386, 1995). We therefore analyzed in closer detail changes in the affinity of CYP51A1 for azole antifungal agents. A strategy consisting of functional expression in Saccharomyces cerevisiae of the C. albicans CYP51A1 genes of sequential clinical isolates from patients was designed. This selection, which was coupled with a test of susceptibility to the azole derivatives fluconazole, ketoconazole, and itraconazole, enabled the detection of mutations in different cloned CYP51A1 genes, whose products are potentially a...Continue Reading

References

Dec 1, 1992·Antimicrobial Agents and Chemotherapy·H vanden BosscheM C Coene
Mar 25, 1992·Nucleic Acids Research·D GietzR H Schiestl
Feb 1, 1990·Biochemical Society Transactions·H Vanden BosscheP A Janssen
Jun 1, 1988·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·P F WatsonS L Kelly
Dec 1, 1972·Biochemical Pharmacology·C F WilkinsonT O Yellin
Jan 1, 1995·Pharmacology & Therapeutics·H Vanden BosscheH Moereels
Jan 1, 1995·Antimicrobial Agents and Chemotherapy·J H RexM A Pfaller
Jan 1, 1994·Journal of Medical and Veterinary Mycology : Bi-monthly Publication of the International Society for Human and Animal Mycology·H Vanden BosscheO Ronin
Sep 1, 1994·Journal of Molecular Graphics·P E Boscott, G H Grant
Oct 1, 1994·Trends in Microbiology·H Vanden BosscheF C Odds
Feb 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S ReddingM Pfaller
Dec 1, 1993·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·N TroilletJ P Chave
Dec 1, 1996·Antimicrobial Agents and Chemotherapy·G D AlbertsonH F Jenkinson
Apr 15, 1997·FEMS Microbiology Letters·T Joseph-Horne, D W Hollomon
Feb 1, 1996·International Journal of Antimicrobial Agents·F C Odds

❮ Previous
Next ❯

Citations

Sep 19, 2000·Antimicrobial Agents and Chemotherapy·K W HenryT D Edlind
Oct 19, 2000·Antimicrobial Agents and Chemotherapy·H KakeyaJ E Bennett
Nov 19, 2008·Antimicrobial Agents and Chemotherapy·Erwin LampingRichard D Cannon
Feb 27, 2003·Antimicrobial Agents and Chemotherapy·Sophie BrunJean-Philippe Bouchara
Feb 27, 2003·Antimicrobial Agents and Chemotherapy·T M Diaz-GuerraJ L Rodriguez-Tudela
Mar 26, 2003·Antimicrobial Agents and Chemotherapy·Takashi FukuokaScott G Filler
Apr 24, 2003·Antimicrobial Agents and Chemotherapy·Adriana M NascimentoDavid S Perlin
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Dominique SanglardJacques Bille
Jul 25, 2003·Antimicrobial Agents and Chemotherapy·Emmanuelle PinjonDerek J Sullivan
Apr 16, 2009·Clinical Microbiology Reviews·Richard D CannonBrian C Monk
Aug 6, 2002·Current Opinion in Microbiology·Dominique Sanglard
Oct 3, 1998·Antimicrobial Agents and Chemotherapy·A S OrozcoS G Filler
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·Patrick VandeputteJean-Philippe Bouchara
Sep 17, 1999·Journal of Clinical Microbiology·B A Arthington-SkaggsC J Morrison
Sep 18, 2002·Antimicrobial Agents and Chemotherapy·Daisuke KobayashiNaoki Watanabe
May 23, 2002·Antimicrobial Agents and Chemotherapy·Theodore C WhiteDavid A Stevens
Nov 19, 2002·Antimicrobial Agents and Chemotherapy·Lute-Harm ZwiersMaarten A De Waard
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·Antonella LupettiPeter H Nibbering
Aug 11, 2001·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·David LambSteven Kelly
Oct 16, 2001·Antimicrobial Agents and Chemotherapy·H NakayamaY Aoki
Oct 2, 2007·Eukaryotic Cell·Teresa T LiuP David Rogers
Apr 27, 2011·Antimicrobial Agents and Chemotherapy·A P SilvaA G Rodrigues
Apr 1, 2008·Eukaryotic Cell·Leah E Cowen, William J Steinbach
Jan 27, 2016·Mycoses·Sarah Santos GonçalvesArnaldo Lopes Colombo
Mar 21, 2002·The Lancet Infectious Diseases·Dominique Sanglard, Frank C Odds

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allergy & Infectious Diseases (ASM)

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Allergy & Infectious Diseases

Allergies result from the hyperreactivity of the immune system to some environmental substance and can be life-threatening. Infectious diseases are caused by organisms including bacteria, viruses, fungi and parasites. They can be transmitted different ways, such as person-to-person. Here is the latest research on allergy and infectious diseases.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.